Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Risk stratification of MGUS and SMM: current and future perspectives

Meral Beksac • 28 Sep 2023
IMS 2023
Multiple Myeloma Rare Diseases Smoldering Myeloma

Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, shares insights into a session held at this year’s meeting which focused on risk stratification in smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS). Dr Beksac highlights the importance measuring the free light chain (FLC) ratio and M protein when stratifying patients at risk of disease progression. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Meral Beksac

3:36
Ex vivo expanded NK cells for hematological cancer immunotherapy
Meral Beksac • 11 Dec 2023
3:52
EMN19: Dara-VCd in patients with multiple myeloma and extramedullary disease
Meral Beksac • 12 Dec 2023
2:16
The value of the early relapse EBMT score in multiple myeloma
Meral Beksac • 28 Sep 2023
1:30
Exploring the role of upfront autoSCT in multiple myeloma
Meral Beksac • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals